FDA Grants Breakthrough Status to Gastric Surgical System
Hope on the horizon — with an honest caveat.
On October 21, 2026, the FDA granted Breakthrough Device Designation to the Trans-Abdominal Gastric Surgical System, a tool designed to help surgeons perform pyloric dilatation for patients with medically refractory gastroparesis — people whose stomach paralysis has not responded to standard medical therapies. (Reported by Wisevoter, citing Medscape reporting.)
What it is
The system is a 12-mm, single-use percutaneous intragastric trocar. Placed endoscopically, it creates an airtight seal against the gastric wall, and a built-in carbon dioxide insufflation port gives surgeons the access they need to perform the pyloric dilatation procedure.
Early studies reported 85%–96% improvement in gastric emptying and 54%–77% normalization of scintigraphy studies.
What breakthrough status means — and what it does not
The FDA’s Breakthrough Devices Program expedites the development and review of devices that address unmet needs for serious conditions. That is real progress for a patient community with few options.
But breakthrough status is not an approval. It does not mean the device is cleared, approved, or available to patients yet. It must still pass rigorous final FDA review, and it does not guarantee immediate availability.
What this does not change today
This is not a treatment patients can get now. If you are living with gastroparesis, talk with your gastroenterologist about the options available to you today.
GSSI provides non-medical support only — help with hotels, food and grocery cards, and local rides while you are being treated, when funding is available. We do not provide medical treatment or medical advice.
We will keep watching this one and share updates as the device moves through review.
Source: Wisevoter, October 21, 2026 (citing Medscape reporting). General information only, not medical advice.
#Gastroparesis #GastroparesisAwareness #GSSI #MedicalNews #PatientSupport